Welcome to our dedicated page for Xeris Biopharma Holdings SEC filings (Ticker: XERS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Xeris Biopharma Holdings, Inc. filings document the company’s commercial biopharmaceutical operations, financial results and governance as a Nasdaq-listed issuer. Its Form 8-K reports furnish quarterly and annual operating results, business highlights, financial guidance and product-related updates for Recorlev®, Gvoke® and Keveyis®.
The filing record also includes disclosure of Recorlev patent litigation under the Hatch-Waxman Act, involving Orange Book-listed patents and ANDA-related challenges. Proxy materials cover board composition, executive compensation, equity awards, shareholder voting matters and governance practices, while current reports document board changes and compensatory arrangements.
Xeris Biopharma Holdings officer Beth Hecht reported an open-market sale of Company stock. She sold 16,667 shares of common stock at a weighted average price of $6.0588 per share under a pre-arranged Rule 10b5-1 trading plan. After this transaction, she continues to hold 1,176,506 shares directly.
Xeris Biopharma Holdings reported a strong turnaround for the quarter ended March 31, 2026, moving to net income of $2.2 million from a net loss of $9.2 million a year earlier. Total revenue rose to $83.1 million from $60.1 million, driven mainly by Recorlev.
Recorlev net product revenue nearly doubled to $49.8 million, while Gvoke was stable at $20.8 million and Keveyis grew modestly to $11.9 million. Cost of goods sold grew more slowly than revenue, improving gross margin. Operating income reached $7.9 million, supported by higher sales despite increased selling and R&D spending.
Xeris ended the quarter with cash, cash equivalents and restricted cash of $115.8 million and generated $9.9 million of operating cash flow. Long‑term debt remained significant at $221.2 million, including 2028 Convertible Notes and 2029 term loans, and the company continues to invest in its XP‑8121 pipeline and platform partnerships.
Xeris Biopharma Holdings, Inc. reported a strong first quarter of 2026 with total revenue of $83.1 million, up 38% from $60.1 million a year earlier. Net product revenue rose 43% to $82.5 million, driven mainly by Recorlev, whose net revenue increased 95% to $49.8 million, while Gvoke was flat and Keveyis grew 4%.
Gross margin improved to 87% from 85%. Operating expenses increased as the company invested in R&D for XP-8121 and expanded its commercial organization, particularly for Recorlev. Despite higher costs, Xeris generated net income of $2.2 million, compared with a net loss of $9.2 million in the prior-year quarter, and Adjusted EBITDA increased to $15.1 million from $4.4 million.
The company tightened full-year 2026 total revenue guidance to a range of $380 million to $390 million, which it states represents more than 30% growth at the midpoint, and highlighted plans to initiate a Phase 3 trial of XP-8121 later in 2026.
Xeris Biopharma Holdings officer Beth Hecht completed an open-market sale of 16,667 shares of common stock at a weighted average price of $6.2282 per share. After the sale, she directly holds 1,193,173 shares. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Xeris Biopharma Holdings, Inc. is asking shareholders to vote at its virtual 2026 Annual Meeting on June 4, 2026 at 8:00 a.m. Central Time. Shareholders of record on April 14, 2026, when 172,625,762 common shares were outstanding, are entitled to vote.
Investors will elect two Class II directors to serve until 2029, ratify Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, and approve on a non-binding advisory basis the compensation of named executive officers. The board recommends voting in favor of all three proposals.
The meeting will be held entirely online via www.proxydocs.com/XERS, with advance registration required by June 3, 2026. The proxy describes board structure, committee responsibilities, director independence, director compensation, and corporate governance policies, including stock ownership guidelines and a code of business conduct and ethics.
Xeris Biopharma Holdings, Inc. reported that Dr. Jeffrey Sherman will retire from its Board of Directors and will not stand for reelection at the 2026 Annual Meeting of Stockholders. He has served as a director since 2021 and sits on the Compensation Committee and the Nominating and Corporate Governance Committee.
The company stated that Dr. Sherman’s decision is not due to any disagreement regarding operations, policies, or practices. When his term ends at the 2026 Annual Meeting, the Board size will be reduced from eight to seven directors.
Xeris Biopharma Holdings, Inc. officer Beth Hecht reported an open-market sale of 16,667 shares of common stock at a weighted average price of $5.9914 per share. After this transaction, she directly owns 1,209,840 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan.
Xeris Biopharma Holdings director Brady James Aloysius sold 10,834 shares of common stock in an open-market transaction. The shares were sold at a weighted average price of $5.5414 per share under a Rule 10b5-1 trading plan. Following the sale, he directly holds 89,166 shares. The sale price reflects multiple trades in a range from $5.29 to $5.63 per share.